Skip to content

Audio Technology To Detect Lung Cancer Earlier

Audio Technology To Detect Lung Cancer Earlier

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03566862
Enrollment
20
Registered
2018-06-25
Start date
2017-05-16
Completion date
2018-11-30
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough, Lung Neoplasms

Brief summary

A cross-sectional study of prospectively collected cough audio recordings using spectral analysis.

Detailed description

In the UK lung cancer is the leading cause of cancer death, also, UK survival rates are poorer compared to other European countries. Lung cancer is plagued by late presentation; 70% present with advanced incurable disease and a third die within 90 days of diagnosis. As such, there is a clear and urgent need to achieve earlier diagnosis of lung cancer. Symptomatic presentation is the most common route to lung cancer diagnosis and symptoms may be present for many months before diagnosis, even in early stage disease. The most common (68%) presenting symptom is cough. Unfortunately cough is also common with other illnesses. Furthermore, a high proportion of those at high-risk of lung cancer have pre-existing cough or respiratory disease (e.g. ex- or current- smokers, patients with chronic obstructive pulmonary disease (COPD)). Cough sounds are known to vary according to underlying lung pathology and could therefore have diagnostic value. Potentially, there may be unique cough and/or respiratory sounds or patterns associated with lung cancer that are not detectable by the human audio spectrum. Identification of a tool that accurately discriminates lung cancer cough could be pivotal. This is a prospective cross-sectional study that will involve subjective analysis of spectrograms of cough recorded from individuals with normal lungs, individuals at high-risk for lung cancer (COPD and other chronic lung diseases) and individuals with lung cancer. 24 hour ambulatory audio recordings will be prospectively collected from patients attending respiratory medicine clinics at Queen Elizabeth University Hospital (QEUH), Glasgow. Participants will be given a free-field lapel microphone and mp3 recorder for 24h. The Leicester Cough Monitor (LCM) will be used to extract the cough sounds from the 24h recordings. The LCM is an automated cough detection system that was developed by Dr Surinder Birring (Kings College Hospital). It uses an algorithm to automatically identify cough sounds from audio recordings, which is then able to provide data on cough frequency. As part of this process, the LCM splices out 1 second sound clips for all parts of the audio recordings that are identified as being (i) a cough sound or (ii) a non-cough sound.

Interventions

DIAGNOSTIC_TESTLeicester Cough Monitor (LCM)

The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.

Sponsors

University of the West of Scotland
CollaboratorOTHER
King's College Hospital NHS Trust
CollaboratorOTHER
Queen Mary University of London
CollaboratorOTHER
NHS Greater Glasgow and Clyde
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 50 years and above and who are either: * Normal Smokers - individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment); * COPD - individuals with a confirmed diagnosis of COPD according to established criteria; * Other (non-COPD) chronic lung disease - individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma); * Lung cancer - individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough

Exclusion criteria

* Participants with an active or recent lung infection, as defined by either the production of purulent sputum associated with systemic symptoms or fever, and/or the receipt of antibiotics for lung infection or acute exacerbation over the 2 weeks preceding the date of consent * Participants who are unable to provide informed consent * Participants who are receiving/have previously received radiotherapy to the lungs * Participants who are currently receiving chemotherapy

Design outcomes

Primary

MeasureTime frameDescription
Spectral centroid (Hz) measurement12 monthsSpectral centroid (Hz) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples

Secondary

MeasureTime frameDescription
Spectral crest factor (Hz) measurement12 monthsSpectral crest factor (Hz) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral flatness (adimensional) measurement12 monthsSpectral flatness (adimensional) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral flux (Watts²) measurement12 monthsSpectral flux (Watts²) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral roll-off (Hz) measurement12 monthsSpectral roll-off (Hz) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Ratio f50 vs f90 (adimensional) measurement12 monthsRatio f50 vs f90 (adimensional) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral bandwith (Hz) measurement12 monthsSpectral bandwith (Hz) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral Renyi entropy (adimensional) measurement12 monthsSpectral Renyi entropy (adimensional) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral kurtosis (adimensional) measurement12 monthsSpectral kurtosis (adimensional) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral skewness (adimensional) measurement12 monthsSpectral skewness (adimensional) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral entropy (adimensional) measurement12 monthsSpectral entropy (adimensional) measurement of cough sounds to ascertain any similarities or differences in spectral characteristics between samples
Spectral peak entropy (adimensional measurement)12 monthsSpectral peak entropy (adimensional measurement) of cough sounds to ascertain any similarities or differences in spectral characteristics between samples

Countries

United Kingdom

Contacts

Primary ContactJoanne McGarry
Joanne.McGarry@ggc.scot.nhs.uk01412321818

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026